Our technologies

Technology Lipido-Colloid (TLC)

Introduction to the technology

tlc_2014TLC healing matrix is an exclusive innovation patented by Urgo Medical. It combines hydrocolloid particles and fatty substances (lipido-colloid particles) held in a non-occlusive fine mesh or within a soft-adherent layer. This technology creates a moist environment, favourable to the healing process.

 

 

TLC technology

To find out more

tlc-healing-matrixTLC is a healing matrix incorporating hydrocolloid particles and fatty substances. TLC creates a favourable moist environment for healing wounds, encourages the natural proliferation of fibroblasts and optimizes skin cell organization. The TLC healing matrix enables harmonious reconstruction of the dermis and epidermis.
TLC dressings do not adhere to the wound, enabling atraumatic treatment and painfree removal.

The efficacy, tolerability and safety of TLC dressings have been evaluated on more than 36,000 patients drawn from 170 clinical areas across Europe, with over 600 clinicians involved in these evaluations. Together, these combined results provide the evidence that TLC dressings promote healing, prevent pain and trauma at dressing change and improve patients’ quality of life. Dressings with TLC Technology are available in a range of sizes and styles to suit all types of wounds.

 

Benefits of TLC Technology

  • Optimisation of healing
  • Moist wound healing
  • Pain-free and atraumatic dressing changes
  • Fibroblast proliferation
  • Protection and improvement of surrounding skin
  • Can be left in place for up to 7 days
  • Clinically proven in more than 36,000 patients
  • Available in a wide range of dressings

 

Indications

TLC dressings are indicated for the local treatment of acute and chronic wounds. For specific indications see individual product information.

 

Mode of action

When in contact with wound exudate, the lipido-colloid particles gels and creates a moist environment. The TLC healing matrix optimises healing and stimulates fibroblast proliferation and ensures non-adherence and pain-free dressing changes.

 

Products with TLC

UrgoTul, UrgoTul Lite, UrgoTul Lite Border, UrgoTul Absorb, UrgoTul Absorb Border, UrgoClean

 

Clinical evidence

For a review of the clinical evidence for TLC dressings please click here

TLC-Ag Technology

Introduction to the technology

tlc_ag_2014TLC-Ag is the combination of Urgo Medical’s unique Technology Lipido-Colloid (TLC) with the antibacterial action of silver salts for the management and prevention of infection.

 

 

TLC Ag Technology

To find out more

Silver salts have a bactericidal effect on most micro-organisms involved with secondary infection: MRSA, Staphylococcus aureus, Pseudomonas aeruginosa etc.

The antimicrobial effect of the TLC-Ag absorbent dressing on the bacterial biofilms of S. aureus (99.97% reduction) and P. aeruginosa (99.98% reduction after 1 day of contact) was demonstrated in an in vitro model.
The dressings are non-adherent to the wound, allowing protection of newly formed tissue and enabling pain free dressing change even after 7 days. No pain means no trauma and a better quality of life for patients, making TLC extremely well tolerated.

 

Benefits of TLC-Ag Technology

  • Broad spectrum antibacterial efficacy, including MRSA
  • 99.9% removal of biofilms after 1 day (Pseudomonas aeruginosa, Staphylococcus aureus)
  • All the benefits of TLC Technology

 

Indications

TLC-Ag dressings are indicated for the local treatment of acute and chronic wounds at risk of infection. For specific indications see individual product information.

 

Mode of action

In contact with wound exudate, the silver sulphate breaks down
(Ag2S04 = 2Ag+ + S042-) and releases Ag+ ions, while the hydrocolloid (carboxymethylcellulose or CMC) particles become hydrated and swell to form a lipido-colloid film.

This controlled prolonged release of Ag+ guarantees continuous antibacterial efficacy.

More details of the action of silver in fighting infection

Role of silver in fighting infection

Silver salts are used in the treatment of wounds with high bacterial colonisation due to their antibacterial properties.
Silver is only active in its Ag+ ionic form. It is unique in this classification since it is neither a genuinely antiseptic nor a genuinely antibiotic treatment and for this reason it is classified as an antibacterial agent. The silver ion has a broad spectrum of activity that covers most micro-organisms associated with the colonisation of chronic wounds. It acts on numerous targets and is bactericidal at very low concentrations, thereby minimising the potential risk of resistance:

  • inhibits the bacterial DNA replication process
  • reduces the bacterial-cell wall strength
  • increases the permeability of the bacterial cytoplasmic membrane
  • inhibits the respiratory enzymes causing asphyxia of the bacteria

It is important to note that silver has no cytotoxicity that hinders the healing process.

 

Silver Sulphate

In contact with wound exudate, the silver salt dissociates and releases the silver ions (Ag+). The release of Ag+ from silver sulphate and the bioavailability of Ag+ at the dressing-wound interface are dependent on exudate. It is in this activated form that the silver ions can exert their anti-bacterial action. This controlled release of Ag+ to the interface guarantees a continuous and extended activity while the dressing is in place.

 

Inhibition of bacterial DNA replication process

Once they are released, the silver ions rapidly react with bacterial DNA and are substituted for hydrogen ions, linking the two nitrogen atoms of the paired bases on the DNA of the bacteria.
This substitution blocks DNA duplication and bacterial replication. The bacteria are therefore unable to replicate and protein synthesis is blocked.

 

Products with TLC-Ag

UrgoTul Ag/Silver, UrgoTul Ag Lite, UrgoTul Ag Lite Border, UrgoCell Ag/Silver, UrgoCell Ag Border

 

Clinical evidence

For a review of the clinical evidence for TLC-Ag dressings please click here

TLC-NOSF Technology

Introduction to the technology

tlc_nosf_2014TLC-NOSF is the combination of Urgo Medical’s unique Technology Lipido-Colloid (TLC) with NOSF (Nano-Oligo Saccharide Factor), a compound with a chemical structure derived from the oligosaccharide family with known anti-proteinase properties.

 

 

TLC NOSF Technology

To find out more

Combined with the other ingredients in the TLC healing matrix, NOSF preferentially binds to the damaged zones, exerting its anti-metalloproteinase activity.
In leg ulcers, pressure ulcers and diabetic foot ulcers, abnormally high levels of proteolytic activity have been identified (up to 65 times more than normal), due to the in situ release of MMPs (Matrix Metalloproteinases). In this micro-environment, TLC-NOSF corrects any metabolic imbalance by limiting the detrimental effect of MMPs on the protein degradation of the Extracellular Matrix components, thereby accelerating healing.

 

Benefits of TLC-NOSF Technology

  • Faster wound healing
  • Cost-effective treatment
  • Improvement of patients’ quality of life
  • All the benefits of TLC Technology

 

Indications

TLC- NOSF dressings are indicated for the local treatment of leg ulcers, pressure ulcers, diabetic foot ulcers and longstanding acute wounds.

 

Mode of action

NOSF neutralises excess proteases, rebalancing the wound equilibrium and promoting faster healing. TLC creates a moist environment, promotes fibroblast proliferation and ensures non-adherence and pain-free dressing change.

 

Products with TLC-NOSF

UrgoStart, UrgoStart Contact

 

Clinical evidence

For a review of the clinical evidence for TLC-NOSF dressings please click here

PresSure System

Introduction to the Technology

The PresSure system is bandage application technology exclusive to UrgoMedical, which aids the application of the two layer compression bandage system, UrgoK2 enabling healthcare professionals achieve the correct, recommended therapeutic pressure (average 40 mmHg) every time, from the first application. Use of the PresSure system ensures optimal, safe, accurate pressure application, ease of use and improved patient comfort and concordance when in compression therapy.

Each bandage is printed with a pressure indicator in the shape of an ellipse.

  • When the bandage is stretched correctly, the ellipse becomes a circle showing that the bandage has been correctly applied with the recommended therapeutic pressure.
  • The ellipse also helps with the correct bandage overlap.

 

Indications

The PresSure System innovation is available in both UrgoK2 and UrgoK2 Lite:

UrgoK2 is indicated for the treatment of venous leg ulcers, venous oedema and lymphoedema which require full compression.
UrgoK2 Lite is indicated for the treatment of venous and mixed aetiology leg ulcers, venous oedema and lymphoedema, which require a reduced level of compression.

 

Mode of action

Haemodynamic effects of compression

Graduated sustained compression therapy is widely accepted as an essential factor in the management of venous leg ulcers.
External application of compression bandaging affects the haemodynamic and lymphatic functions:

  • Reduction in vein diameter of the superficial and deep venous systems, which improves valve function, reducing venous reflux and improving venous return.
  • Improved capillary filtration and the enforced re-absorption of interstitial fluid into the veins and lymphatic system, helping to reduce levels of oedema and improve skin condition.

Graduated sustained compression therapy is clinically proven to be the most important factor in the management of venous insufficiency. The greater the severity of CVI, the higher the degree of compression must be applied for effective therapeutic treatment. It is widely acknowledged that an applied sub-bandage pressure of 40 mmHg at the ankle, is required for the severe stages of chronic venous insufficiency (CVI) and specifically for the treatment of venous leg ulcers (CEAP level C6), but also once the leg is healed and to reduce oedema.

 

Products with the Pressure System

UrgoK2, UrgoK2 Latex Free, UrgoK2 Lite, UrgoK2 Lite Latex Free

 

Clinical evidence

JWC_18_11_474_Junger-web BJN_17_20_TVS_16_24_Urgo_web urgo-evidence-review-supplement-lr
Comparison of interface pressures of three compression bandaging systems used on healthy volunteers A comparison of interface pressures of three compression bandage systems Efficacy and reproducible
compression of the KTwo
bandage system
Download Download Download
JWC_16_9_385_90_Sauvadet_web    
Efficacy, safety and acceptability of a new two-layer bandage system for venous leg ulcers    
Download    

 For more information on evidence, click here.

Axis of Research

tlc_2014In 12 years of innovation Technology Lipido-Colloid (TLC) has completely revolutionised wound healing. With  a wide range of dressings, well tolerated,  easier to use and playing an active role in the healing process, we have advanced the field of wound care. Today new additions to the range are continuously being designed to further improve the healing process or, when necessary, to diffuse antibacterial components in to the wound bed.

Last update : October 20, 2017